LabCorp shareholders were disappointed at the lower than expected earnings that Laboratory Corporation of America, also known as LabCorp, revealed. Medical laboratory operator Laboratory Corp. of America Holdings said Friday that its net income slipped in the second quarter and lowered its guidance for the full year. This was a major disappointment to analysts and shareholders alike, but not to the patients who have received lackluster service at LabCorp facilities.
Its revenue rose 3 percent but the company said the advance was constrained by reduced Medicare payments, steep federal budget cuts in April, and delays and denials of coverage by some health care payers after new payment codes were introduced. Its shares slipped by midday.
LabCorp said its net income fell to $151.9 million, or $1.62 per share, in the second quarter ended June 30, down from $153.3 million, or $1.56 per share, a year earlier. Revenue rose 3 percent to $1.47 billion from $1.42 billion.
LabCorp said testing volumes rose 5 percent during the quarter, but revenue per request for testing fell 1.8 percent. It said testing for drugs of abuse increased. The company expects to earn between $6.90 and $7.10 per share for the year, down from $6.85 to $7.15 per share.
LabCorp said earlier this year that reduced Medicare payments will cut its annual net income by about 35 cents per share, and it maintained that view on Friday. Analysts are forecasting earnings of $7.08 per share.
The company still expects its annual revenue to grow 2 to 3 percent, which implies a total of $5.78 billion to $5.84 billion. Analysts project $5.79 billion in revenue on average. Shares of LabCorp (NYSE: LH) lost 74 cents on the announcement. As of today, July 26th, shares of LabCorp are trading at around $98 per share.